HEOR & Market Access Intelligence for Oncology

Inform decision-making from a reimbursement perspective

The Market Access Platform (MAP) unlocks critical insights and key decision drivers for Oncology drug therapy pricing. Integrating reimbursement, regulatory, and clinical data, the MAP enables users to link critical factors such as population restrictions in the marketing authorization with patient-reported outcomes in clinical trials. Capturing over two million points of data, the MAP supports evidence-driven decision making from early pipeline to value dossier creation, commercialization, and marketing.

 

Key Oncology questions MAP helps answer:

Kidney Cancer Endpoints.png

Clinical Trial Design

What primary endpoints were commonly used in Kidney Cancer?

How often have single-arm trials been used and how often are they successful in HTA evaluations?

 

Request a live demo

Complete the form below to request a live demo of the Market Access Platform.

Name *
Name
Contact Permission *
By clicking "Yes", I agree to DR/Decision Resources, LLC keeping in touch with me by email in relation to Decision Resources Group’s products, services, news, events and other marketing materials in accordance with our Privacy Policy. We will not share your information outside the Decision Resources Group and will only contact you for the purpose of providing you information on our products and services.
Pembrolizumab Economic Comparators.png

Economic Modeling

What is the most plausible NICE ICER across all reviews in Breast Cancer?

What is the patient population considered in the cost-utility model for pembrolizumab?

 
Gastric Cancer PROs.png

Value Dossier Development

What is the patient population estimate for second-line Non-Small-Cell Lung Cancer in Germany?

What agencies are using patient-reported outcomes (PROs) in assessments for Gastric Cancer?